A newly developed substance could prove key to better treatment of brain tumours, researchers have said.
Scientists from the German Cancer Research Center investigated the effect of a combination of radiation treatment and newly developed substance LY2109761 on the brain injury.
The substance is known to block the signals transmitted into cells by a receptor.
Researchers transplanted the human gliobastoma cells into the brains of mice and found that the animals which received the combination therapy survived longer than those treated by radiotherapy alone.
Under the combination therapy, tumours also grew more slowly, less invasively and exhibited a lower density of newly formed blood vessels.
"Paradoxically, radiation therapy can provoke aggressive growth behaviour in surviving tumour cells. LY2109761 seems to prevent this fatal effect," explained Dr Peter Huber, head of the Radiation Oncology unit at the centre.
This follows a study published in the journal Cancer Cell, which revealed that brain tumours in children operate on a two-tier system - explaining why surgery and radiotherapy halts tumour growth in some patients but not in others.
Written by John Sherrington
